<DOC>
	<DOCNO>NCT01981031</DOCNO>
	<brief_summary>BioChaperone Combo liquid formulation contain Insulin Glargine Insulin Lispro . The aim trial ass efficacy safety BioChaperone® Combo subject type 1 diabetes dose 0.8 U/kg . This trial phase 1 single-center , randomize , double-blinded , two-treatment , two-period cross-over , 30-hour euglycaemic glucose clamp trial subject type 1 diabetes mellitus . Each subject randomly allocate one single dose 0.8 U/kg BioChaperone® Combo one single dose 0.8 U/kg Humalog® Mix 25 two separate dose visit .</brief_summary>
	<brief_title>A Trial Assess Efficacy Safety BioChaperone Combo Humalog Mix 25 Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<criteria>Type 1 diabetes mellitus least ( equal ) 12 month , Treated multiple daily insulin injection insulin pump treatment least ( equal ) 12 month , Body Mass Index ( BMI ) : 18.028.0kg/m2 ( inclusive ) Type 2 diabetes mellitus , The receipt investigational product within 3 month prior first dose , Clinically significant abnormality , judge investigator , Any systemic treatment drug know interfere glucose metabolism , History alcoholism drug/chemical abuse tobacco product within 5 year prior screen Blood plasma donation past month 500mL within 3 month prior screen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>